HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Education
Visit Zacks'
Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


PFE: Pfizer Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

PFIZER INC (NYSE)
PFE 18.36 0.25 (1.38%) Vol.  60,976,316 16:00 ET

Day Low - High 18.12 - 18.48
52wk Low - High 11.62 - 18.48
Avg Volume 50,027,580
Industry MED-DRUGS
Market Cap 123.91 B
Div - Yield 0.64 - 3.49
PE (forward) 9.08
PEG Ratio -12.11
Current Year Est. 2.02
EPS Last Year 2.18
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/18/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
PFIZER INC PFE PREMIUM
SUPERGEN INC SUPG PREMIUM
VALEANT PHARMA VRX PREMIUM
SANTARUS INC SNTS PREMIUM
See all MED-DRUGS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.67
ABR (Last Week) 1.61
# of Recs in ABR 20
Average Target Price 20.75
Industry Rank by ABR 46 out of 217
Rank in Industry 46 out of 113
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate PFE?
Buy
Sell
Find out what the Zacks Community
thinks of PFE at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR PFE
Zacks Blog: Panel Backing for Prevnar 13
Nov 19, 2009
Zacks Blog: MDVN Starts New Alzheimer’s Trials
Nov 18, 2009
Zacks Equity Research: Report for PFE
Nov 18, 2009
Zacks Blog: Another Win for Mylan
Nov 13, 2009
Zacks Blog: Glaxo Reports Higher Revenues
Nov 12, 2009
More Zacks Commentary
NEWS
Pfizer Announced FDA Approved Geodon For Bipolar Disorder (PFE)
Nov 20, 2009
Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
Nov 20, 2009
Pfizer Announced FDA Approved Revatio Injection (PFE)
Nov 20, 2009
PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts, November 20, 2009: CNO, NRG, NOC, PFE, ANW and BSX
Nov 20, 2009
Sector Update: Health Care Shares Lower in Pre-Market Session - Merck Approved for Elonva by CHMP in EU
Nov 20, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.48 0.56 2.02 2.24
Number of Estimates 15 4 19 16
Low Estimates 0.37 0.51 1.99 2.00
High Estimate 0.52 0.63 2.05 2.45
Year Ago EPS 0.65 0.54 2.42 2.02
EPS Growth -25.74% 3.24% -16.46% 10.90%

More Estimates

COMPANY DESCRIPTION
Pfizer Inc is a research-based, global pharmaceutical company that discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. Pfizer has three business segments: health care, animal health and consumer health care. Its products are available in numerous countries. (Company Press Release)

Full Company Report
FINANCIALS
EPS TTM 2.18
Sales 48296
Net Income 8134
Price/Earnings 8.42
Price/Book 1.87
Price/Cash Flow 5.77
Price/Sales 2.7


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research